Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.45 |
| ▸ | LCAT | P04180 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.40 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.37 |
| ▸ | MTOR | P42345 | 4/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | TTK | P33981 | 1/20 | 0.35 |
| ▸ | PLK1 | P53350 | 1/20 | 0.35 |
| ▸ | OGA | O60502 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2702630 | 1.00 | CHRNB2 (0.45) | CHRNB2CHRNA4LCATCHRNB4CHRNA3 | |
| SCHEMBL550890 | 1.00 | CHRNB2 (0.45) | CHRNB2CHRNA4LCATCHRNB4CHRNA3 | |
| SCHEMBL550891 | 1.00 | CHRNB2 (0.45) | CHRNB2CHRNA4LCATCHRNB4CHRNA3 | |
| SCHEMBL2702628 | 1.00 | CHRNB2 (0.45) | CHRNB2CHRNA4LCATCHRNB4CHRNA3 | |
| SCHEMBL549801 | 1.00 | CHRNB2 (0.45) | CHRNB2CHRNA4LCATCHRNB4CHRNA3 | |
| SCHEMBL550785 | 0.87 | PIK3CA (0.41) | PIK3CAMTORAKT1RETHSD11B1 | |
| SCHEMBL2700496 | 0.87 | PIK3CA (0.41) | PIK3CAMTORAKT1RETHSD11B1 | |
| SCHEMBL551857 | 0.87 | PIK3CA (0.41) | PIK3CAMTORAKT1RETHSD11B1 | |
| SCHEMBL549739 | 0.84 | CYP3A4 (0.41) | HSD11B1HRH3 | |
| SCHEMBL550796 | 0.84 | CYP3A4 (0.41) | HSD11B1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8563570-B2 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2013-10-22 | — | — | US | claimed |
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2009-11-26 | — | — | US | claimed |
| US-8563570-B2 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2013-10-22 | — | — | US | disclosed |
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-05-17 | — | — | US | disclosed |
| US-8110581-B2 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110581-B2 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110581-B2 | Lactam compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2012-02-07 | — | — | US | disclosed |
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291946-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | HSD11B1, HSD11B2, HSD17B1 | CHRNB2 3309/4885CHRNA4 3531/4885LCAT 661/4885 |
| US-20120122858-A1 | LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | HSD11B1, HSD11B2, HSD17B1 | CHRNB2 3309/4885CHRNA4 3531/4885LCAT 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.